Phibro Animal Health | PAHC - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
Align Technology USD 683.59M 44.39M 2025-12
ANI Pharmaceuticals USD 124.18M 12.39M 2025-12
Assertio Holdings USD 22.24M 970K 2024-06
Aurora Cannabis CAD 46.62M 14.33M 2025-12
Bristol-Myers Squibb USD 8.79B 110M 2025-09
Canopy Growth CAD 21.47M 434K 2025-12
Corcept Therapeutics USD 199.58M 3.46M 2025-12
Eli Lilly USD 14.59B 1.48B 2025-09
Henry Schein USD 1.06B 37M 2025-12
Idexx Laboratories USD 658.11M 25.24M 2025-12
Knight Therapeutics CAD 64.72M 8.91M 2025-12
Merck USD 13.42B 431M 2025-09
Nektar Therapeutics USD 13.75M 650K 2024-06
Pacira USD 142.25M 11.34M 2025-12
Phibro Animal Health USD 133.5M 12.6M 2025-12
Prestige Brands USD 157.37M 5.79M 2025-12
Supernus Pharmaceuticals USD 164.04M 15.23M 2025-12
Zoetis USD 1.64B 73M 2025-12